Metagenomics Next-generation Sequencing Approach to Detect Microbial DNA/RNA Overtime in Individuals Undergoing Hematopoietic Stem Cell Transplant
Part of paid clinical trials in Bethesda, Maryland.
- Sponsor
- National Institutes of Health Clinical Center (CC)
- Study ID
- NCT06904053
- Status
- Recruiting
Conditions
- Hematopoietic Stem Cell Transplantation
Eligibility Criteria
- Sex
- ALL
- Age
- 3 Years - 100 Years
- Healthy Volunteers
- Not accepted
Study Details
Infections are a major cause of morbidity and mortality in patients undergoing hematopoietic stem cell transplant (HSCT). The purpose of this study is to evaluate if metagenomic next-generation sequencing (mNGS) can detect microbial signatures in people undergoing HSCT, and if microbial identification can be correlated with clinical features of infection (e.g., fever). Participants undergoing HSCT as part of other studies at the NIH Clinical Center (CC) will provide blood before the transplant and through 6 months after. Total nucleic acid will be extracted from plasma and subjected to mNGS. The primary objective of this study is to investigate if by using plasma and an mNGS approach, we can detect bacterial, fungal, protozoan, or viral DNA/RNA over time, in immunocompromised patients undergoing transplantation. Secondary objectives are to: (1) To correlate microbial identification with episodes of fever or clinical suspicion of infection; and to (2) correlate change in microbial signatures in patients with suspected immune reconstitution inflammatory syndrome. The study is conducted at the NIH Clinical Center. Participants, aged 3 years and older, on other research studies at the NIH CC who are undergoing HSCT are invited to take part of this study. Expected participation is up to six months.
Key Dates
- Start date
- Apr 9, 2025
- Status verified
- Apr 2026
- Primary completion
- Nov 1, 2027
- Completion
- Dec 30, 2030
Study Design
- Enrollment
- 30 participants (estimated)
Arms
- Arm: All HSCT patientsMale or female, aged 3 years or older.
Primary Outcome Measure
Any positive clinical results for each of 5 pathogen categories [ Time Frame: Six months ]
Central Contacts
- Mary M Czech, M.D.(240) 447-9109
- Sanchita Das, M.D.(301) 496-5668
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| National Institutes of Health Clinical Center | Bethesda | Maryland | 20892 |
Find similar trials in Bethesda, MD
Related Studies
- Long-Term Follow-up of People Undergoing Hematopoietic Stem Cell TransplantationRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) SyndromePHASE2 · Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell TransplantationPHASE1/PHASE2 · Recruiting · National Cancer Institute (NCI) · Duarte, California
- Longitudinal Early Advance Care Planning Discussions and Documentation (LEADD) Program: An Exploratory Study in Adolescents and Young Adults (AYAs) Receiving Hematopoietic Stem Cell TransplantRecruiting · National Cancer Institute (NCI) · Baltimore, Maryland